Pediatric status epilepticus management by Emergency Medical Services (the pSERG cohort).

Delayed treatment in status epilepticus (SE) is independently associated with increased treatment resistance, morbidity, and mortality. We describe the prehospital management pathway and Emergency Medical Services (EMS) timeliness in children who developed refractory convulsive status epilepticus (RCSE). Retrospective multicenter study in the United States using prospectively collected observational data from June 2011 to March 2020. We selected pediatric patients (one month-21 years) with RCSE initiated outside the hospital and transported to the hospital by EMS. We included 91 patients with a median (percentile In this multicenter study of pediatric RCSE, prehospital treatment may be streamlined further. Patients with a history of SE were more likely to receive prehospital rescue medication.

Informations de copyright

Copyright © 2023. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of Competing Interest M.A.G. was supported by Fundación Alfonso Martín Escudero and the Epilepsy Research Fund. I.S.F. was supported by Fundación Alfonso Martín Escudero, the HHV6 Foundation, and the Epilepsy Research Fund. R.A. receives research support from NIH NINDS R01 NS115929 and Procter Foundation (Procter Scholar Award 2018–2021). C.B.A. was supported by Fundación Alfonso Martín Escudero. J.N.B. has served as a consultant for Novartis. T.A.G. is funded by NIH grants 2U01-NS045911, U10-NS077311, R01-NS053998, R01-NS062756, R01- NS043209, R01-LM011124, and R01-NS065840. He has received consulting fees from Supernus, Sunovion, Eisai, and UCB. He also serves as an expert consultant for the US Department of Justice and has received compensation for work as an expert on medico-legal cases. He receives royalties from a patent license. E.J.N. is a professional advisory board of the Epilepsy Foundation of America and served on Advisory Board for Zogenix. J.J.R. is a member of a data safety monitoring board for GW Pharmaceuticals. His-spouse is an editor for Uptodate. D.T. receives research funding from Children's Miracle Network Hospitals and has previously received consultation fees from Gerson Lehrman Group, Guidepoint, IQVIA, and bioStrategies Group. M.S.W. serves as a scientific consultant and on the clinical advisory board for Sage Pharmaceuticals. A.W. receives research funding from Novartis, Eisai, Pfizer, UCB, Acorda, Lundbeck, GW Pharma, Upsher-Smith, and Zogenix and receives publication royalties from Up to date. T.L. is part of pending patent applications to detect and predict seizures and diagnose epilepsy. He receives research support from the NIH, the Epilepsy Research Fund, the Epilepsy Foundation of America Epilepsy Venture Fund (Shark Tank Award), MIKU, and Epitel. He received device donations from Epitel, MIKU, Empatica, and neuroelectrics. In the past, he received research grants from Sage, Lundbeck, Eisai, Upsher-Smith, Proximagen, UCB, Mallinckrodt, Pfizer, and Empatica. In the past, he served as a consultant for Engage and Upsher Smith. The remaining authors have no disclosures relevant to this manuscript.